

Dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in laryngeal and hypopharyngeal cancer patients

Submission date 17/01/2011	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 31/03/2011	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 27/11/2025	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-study-looking-increasing-dose-radiotherapy-treat-cancer-voice-box-or-lower-part-of-the-throat-art-deco>

Contact information

Type(s)

Scientific

Contact name

Dr Christopher Nutting

Contact details

Director Head and Neck Unit, Consultant Reader in Oncology
Royal Marsden NHS Foundation Trust
Head and Neck Unit
Royal Marsden Hospital
Fulham Road
London
United Kingdom
SW3 6JJ

Additional identifiers

Protocol serial number

ICR-CTSU/2009/10022

Study information

Scientific Title

A randomised multicentre accelerated radiotherapy study of dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers

Acronym

ART-DECO

Study objectives

To determine the potential of dose escalated intensity modulated radiotherapy (IMRT) to improve locoregional failure free rate (LRFFR) and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central London Research Ethics Committee (REC) 4 approved on 18/10/2010 (ref: 10/H0715/48)

Primary study design

Interventional

Study design

Parallel group phase III multicentre randomized controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Locally advanced squamous cell cancers of the larynx or hypopharynx

Interventions

The dose escalated IMRT (experimental) treatment group will receive 67.2 Gy in 28 fractions (2.4 Gy per fraction) to the involved site and nodal groups and 56 Gy in 28 fractions (2.0 Gy per fraction) to nodal areas at risk of harbouring microscopic disease.

The standard dose IMRT (standard) treatment group will receive 65 Gy in 30 fractions (2.167 Gy per fraction) to the involved site and nodal groups and 54 Gy in 30 fractions (1.8 Gy per fraction) to nodal areas at risk of harbouring microscopic disease.

All patients will receive concomitant cisplatin 100 mg/m² on day 1 and day 29 of the radiotherapy schedule however within the context of this trial, chemotherapy is not an investigational medicinal product.

Added 27/11/2025:

Additional Data Linkage Information:

Participants from this trial will also be included in the INTERACT project which will link to their

data held by NHS England. For more information, please see the INTERACT website: <https://www.icr.ac.uk/interact>.

Intervention Type

Other

Primary outcome(s)

Locoregional failure free rate (LRFFR).

Measured at 1, 2, 3, 4 and 8 weeks post-treatment and at 3, 6, 12, 18 and 24 months post treatment. Patients will then be followed up annually up to 5 years.

Key secondary outcome(s)

1. Laryngo-oesophageal dysfunction free rate
 2. Overall survival (time from randomisation to death)
 3. Acute and late toxicities following chemoradiation
 4. Characteristics of patients who proceed to salvage neck dissection
 5. Characteristics of patients who fail organ preservation
- All of the above will be measured at 1, 2, 3, 4 and 8 weeks post-treatment and at 3, 6, 12, 18 and 24 months post treatment. Patients will then be followed up annually up to 5 years.
6. Patient assessed quality of life, measured using questionnaires administered at baseline, end of radiotherapy treatment, 6 months, 1 year and then annually to 5 years post-treatment

Completion date

01/12/2020

Eligibility

Key inclusion criteria

1. Aged 16 years or above, either sex
2. Histologically confirmed squamous cell cancer of the larynx or hypopharynx
3. Chemo-radiotherapy is the investigators treatment of choice. Induction chemotherapy is permitted.
4. Locally advanced squamous cell cancer of the larynx or hypopharynx i.e. stage III or IV a/b disease
5. World Health Organization (WHO) performance status of 0 or 1
6. Creatinine clearance of greater than 50 ml/min
7. Must be suitable to attend long term follow-up. All patients participating in the QoL study must have adequate cognitive ability to complete the QoL questionnaires.
8. Written informed consent

Patients may undergo surgical biopsy or non-radical surgery prior to study entry.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

16 Years

Upper age limit

100 Years

Sex

All

Total final enrolment

276

Key exclusion criteria

1. Previous radiotherapy to the head and neck region
2. Clinical evidence of metastatic disease (Stage IVc)
3. Previous malignancy except non-melanoma skin cancer and early stage cancer in remission for at least 5 years following treatment
4. Previous or concurrent illness, which in the investigator's opinion would interfere with completion of therapy
5. Pre-existing previous speech or swallowing problems unrelated to the diagnosis of cancer
6. Large primary tumour, where organ preservation is unrealistic

Date of first enrolment

01/02/2011

Date of final enrolment

20/10/2015

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Head and Neck Unit

-

London
England
SW3 6JJ

Sponsor information

Organisation

Royal Marsden NHS Foundation Trust (UK)

ROR

<https://ror.org/0008wzh48>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK) (ref: CRUK/10/018)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		10/07/2021	14/07/2021	Yes	No
Plain English results		10/03/2022	24/03/2022	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes